This Viewpoint proposes an expansion of state-run prescription-drug monitoring programs to meet the need for broader pharmacovigilance given the shift to alternative payment methods that bypass traditional insurance claims.
Ashlee N. Mattingly (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: